norfluoxetine has been researched along with Depression in 10 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 9.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 5.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 5.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 1.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| " A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0." | 1.31 | Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. ( Gatti, G; Guarneri, L; Jannuzzi, G; Magni, P; Pacifici, R; Perucca, E; Spina, E; Torta, R; Zuccaro, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Sagahón-Azúa, J | 1 |
| Medellín-Garibay, SE | 1 |
| Chávez-Castillo, CE | 1 |
| González-Salinas, CG | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Benham, RS | 1 |
| Hewage, NB | 1 |
| Suckow, RF | 1 |
| Engin, E | 1 |
| Rudolph, U | 1 |
| Jannuzzi, G | 1 |
| Gatti, G | 1 |
| Magni, P | 1 |
| Spina, E | 1 |
| Pacifici, R | 1 |
| Zuccaro, P | 1 |
| Torta, R | 1 |
| Guarneri, L | 1 |
| Perucca, E | 1 |
| Thompson, MR | 1 |
| Li, KM | 1 |
| Clemens, KJ | 1 |
| Gurtman, CG | 1 |
| Hunt, GE | 1 |
| Cornish, JL | 1 |
| McGregor, IS | 1 |
| Cook, JW | 1 |
| Spring, B | 1 |
| McChargue, DE | 1 |
| Borrelli, B | 1 |
| Hitsman, B | 1 |
| Niaura, R | 1 |
| Keuthen, NJ | 1 |
| Kristeller, J | 1 |
| el-Yazigi, A | 1 |
| Chaleby, K | 1 |
| Gad, A | 1 |
| Raines, DA | 1 |
| Brunswick, DJ | 1 |
| Amsterdam, JD | 1 |
| Fawcett, J | 1 |
| Quitkin, FM | 1 |
| Reimherr, FW | 1 |
| Rosenbaum, JF | 1 |
| Beasley, CM | 1 |
| Burch, KJ | 1 |
| Wells, BG | 1 |
| Wong, SH | 1 |
| Dellafera, SS | 1 |
| Fernandes, R | 1 |
| Kranzler, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00113737] | 0 participants | Interventional | 1998-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for norfluoxetine and Depression
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
2 trials available for norfluoxetine and Depression
| Article | Year |
|---|---|
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Moda | 2004 |
Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.
Topics: Adolescent; Adult; Amitriptyline; Bipolar Disorder; Chromatography, High Pressure Liquid; Depression | 1995 |
7 other studies available for norfluoxetine and Depression
| Article | Year |
|---|---|
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Topics: Adult; Antipsychotic Agents; Anxiety; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome | 2021 |
Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABA
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dose | 2017 |
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Depression; Female; Fluoxetine; Humans; Male; Mental | 2002 |
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig | 2004 |
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
Topics: Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndro | 2001 |
Fluoxetine/norfluoxetine concentrations in human milk.
Topics: Adult; Breast Feeding; Depression; Female; Fluoxetine; Humans; Infant; Infant, Newborn; Milk, Human; | 1992 |
Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Clomipramine; Depression; Fluoxetine; Humans | 1990 |